Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.
Zomedica Corp. (NYSE American: ZOM) is a veterinary health company based in Ann Arbor, Michigan, focused on creating innovative products for companion animals, including dogs, cats, and horses. The company addresses the unmet needs of clinical veterinarians through its diverse product portfolio that includes diagnostic and therapeutic devices aimed at enhancing both patient and practice health.
Core Business:
Zomedica specializes in the development and commercialization of veterinary diagnostic tools and pharmaceutical products. Their flagship product, the TRUFORMA® platform, uses Bulk Acoustic Wave (BAW) technology to offer highly sensitive and accurate point-of-care diagnostics for thyroid and adrenal disorders in dogs and cats. The TRUFORMA system empowers veterinarians to make timely and precise diagnostic decisions directly within their clinics, eliminating the delays associated with sending samples to external laboratories.
Recent Achievements:
Recently, Zomedica has expanded its intellectual property portfolio to include 188 patents and 131 trademarks, offering robust protection for its innovative products. This portfolio includes newly issued patents that enhance the TRUFORMA system's capability to detect a wider array of health conditions.
Current Projects:
The company is working on expanding its product range and market reach. The recent CE certification for the VetGuardian® remote contactless monitoring system paves the way for Zomedica's expansion into the European veterinary market. Additionally, the company has launched an improved canine cortisol assay and Over-the-Air (OTA) software update capabilities for the TRUFORMA platform, making it easier for veterinarians to access the latest diagnostic tools and features.
Financial Condition:
For the first quarter of 2024, Zomedica reported a 14% increase in revenue to $6.3 million, driven by growth in both its diagnostic and therapeutic segments. The company's gross margin stood at 66%, and it holds $90.9 million in cash and available-for-sale securities as of March 31, 2024.
Market Position:
With an estimated total addressable market of $2.5 billion annually for its diagnostic and therapeutic products, Zomedica is well-positioned to capture significant market share. The company's potential customer base includes approximately 4,450 equine or mixed veterinary practices and 30,000 small animal veterinary practices in the United States alone.
Partnerships and Collaborations:
Zomedica collaborates with veterinary researchers to advance animal healthcare through continuous innovation. The company's recent expansion of its global manufacturing and distribution facilities in Roswell, Georgia, aims to support the growing demand for its products.
For more information, visit www.zomedica.com
Zomedica Corp. (NYSE American: ZOM) reported its financial results for the year ended December 31, 2021. The company achieved a total revenue of approximately $4.1 million, a significant increase from $0 in 2020, primarily due to the inclusion of PulseVet results. However, Zomedica reported a net loss of approximately $18.4 million or $0.05 per share. Notable increases included TRUFORMA product revenue, which grew by 224%. As of year-end, the company held $195 million in cash and equivalents.
Zomedica Corp. (NYSE American: ZOM) reported total revenue of $4.1 million for the Fourth Quarter and Full Year 2021, a significant increase from $0 in 2020. The gross margin was an impressive 73.9%. Revenue from PulseVet reached $4.0 million, marking a 66% growth over the previous year. Meanwhile, TRUFORMA product revenue rose by 224% to $73,000 compared to Q3 2021. The company ended the year with $195 million in cash and equivalents. A detailed Form 10-K report will be released on March 1, 2022, followed by a presentation on March 8, 2022.
Zomedica Corp. (NYSE American: ZOM) announces Adrian Lock as the new leader of its sales organization. Lock, previously the CEO of PulseVet, brings a decade of experience in veterinary sales, particularly in equine sports medicine. He aims to enhance Zomedica's sales team while focusing on the growth of the Truforma in-clinic biosensor platform and PulseVet shock wave therapy. CEO Larry Heaton supports this move, highlighting Lock's track record in building sales in the equine market and the potential for expansion into the small animal market.
Zomedica Corp. (NYSE: ZOM) announced key additions to its management team, aiming to bolster future growth. Tony Blair joins as Executive Vice President of Operations, bringing over 35 years of experience, while Kristin Domanski has been appointed as Vice President of Human Resources, focusing on HR excellence. Nicole Westfall will lead marketing efforts as Vice President of Marketing, leveraging her 25 years in the field. Evan Saint-Peter has been promoted to Vice President of Technology Innovation. CEO Larry Heaton expressed confidence in the new team to enhance Zomedica's product offerings and growth strategies.
Zomedica Corp. (NYSE American: ZOM) has provided an update on its marketing initiatives and integration with PulseVet during Q1 2022. The company successfully completed sales training for its field sales team ahead of the VMX Veterinary Meeting, where they jointly showcased their TRUFORMA and ProPulse products. Zomedica plans to continue this collaboration at the upcoming Western Veterinary Annual Conference and other smaller meetings. CEO Larry Heaton emphasized the significance of these events to drive adoption of their technologies and enhance veterinarian engagement.
Zomedica Corp. (NYSE American:ZOM) provided a shareholder update from CEO Larry Heaton, outlining company progress and strategies. The focus is on the commercialization of the TRUFORMA product line, launched in May, alongside the acquisition of Pulse Veterinary Technologies for $71.9 million. Despite delays in new assay development due to COVID-19 and supply chain issues, Zomedica expects to commercialize new assays for adrenal and thyroid diseases in 2022. The company reported a strong balance sheet with $271 million in cash post-acquisition, aiming for further product expansion through strategic acquisitions.
Zomedica Corp. (NYSE American: ZOM) announced that CEO Larry Heaton will present a company overview at the virtual H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 am ET for registered attendees and the public at this link, and on Zomedica's website thereafter. The company focuses on providing innovative diagnostic and therapeutic products for companion animals, aiming to enhance the productivity and revenue for veterinary practices.
Zomedica Corp. (NYSE American: ZOM) reported financial results for Q3 and YTD 2021, highlighting a net loss of approximately $6.3 million or $0.01 per share for Q3, and $15.1 million or $0.05 per share for nine months. Revenue from TRUFORMA® products was $22,514 for Q3 and $52,331 YTD. Selling and administrative expenses surged to $6.1 million in Q3, a 166% increase, driven by share-based compensation and acquisition costs. Zomedica ended September 2021 with approximately $271.4 million in cash, post-PulseVet acquisition, positioning for growth in 2022.
Zomedica Corp. (NYSE American: ZOM) announced the appointment of Larry Heaton as President and future CEO, effective October 1, 2021. Heaton, with over 35 years of experience in medical device and biotechnology sectors, succeeds Robert Cohen, who will retire on October 31, 2021, but remain on the Board. Heaton expressed optimism about Zomedica's growth opportunities, particularly with its TRUFORMA® diagnostic platform and the recent acquisition of PulseVet.
Zomedica Corp. (NYSE American: ZOM) announced the acquisition of Pulse Veterinary Technologies for $70.9 million in an all-cash transaction. PulseVet is a leader in electro-hydraulic shock wave technology used for treating various veterinary conditions. This acquisition aims to expand Zomedica's product offerings and enhance sales capabilities, particularly for PulseVet’s new X-Trode handpiece, which enhances treatment for companion animals. Zomedica’s CEO highlighted the strategic importance of this acquisition in accelerating overall growth.
FAQ
What is the current stock price of Zomedica (ZOM)?
What is the market cap of Zomedica (ZOM)?
What does Zomedica Corp. specialize in?
What is the TRUFORMA® platform?
Where is Zomedica Corp. based?
What recent milestones has Zomedica achieved?
What financial performance did Zomedica report for Q1 2024?
What is the market potential for Zomedica's products?
What are some of Zomedica’s key products?
What is the significance of the CE certification for VetGuardian®?
How does Zomedica support veterinarians?
How can I get more information about Zomedica?
